首页 | 本学科首页   官方微博 | 高级检索  
   检索      


A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione,a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity
Authors:Jerzy R Szewczyk  Chris P Laudeman  Doug M Sammond  Manon Villeneuve  Douglas J Minick  Mary K Grizzle  Alejandro J Daniels  John L Andrews  Diane M Ignar
Institution:1. Department of Medicinal Chemistry, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, United States;2. Department of Metabolic Diseases, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, United States;3. Department of Analytical Chemistry GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, United States;4. Seachaid Pharmaceuticals, Inc. 801 Capitola Drive, Ste. 5 Durham, NC 27713, United States
Abstract:Finding small non-peptide molecules for G protein-coupled receptors (GPCR) whose endogenous ligands are peptides, is a very important task for medicinal chemists. Over the years, compounds mimicking peptide structures have been discovered, and scaffolds emulating peptide backbones have been designed. In our work on GPCR ligands, including cholecystokinin receptor-1 (CCKR-1) agonists, we have employed benzodiazepines as a core structure. Looking for ways to reduce molecular weight and possibly improve physical properties of GPCR ligands, we embarked on the search for molecules providing similar scaffolds to the benzodiazepine with lower molecular weight. One of our target core structures was 1,4-dihydro-1,4]diazepine-5,7-dione. There was not, however, a known synthetic route to such molecules. Here we report the discovery of a simple and concise method for synthesis of 2-6-(1H-indazol-3-ylmethyl)-5,7-dioxo-4-phenyl-4,5,6,7-tetrahydro-1,4]diazepin-1-yl]-N-isopropyl-N-phenyl-acetamide as an example of a compound containing the tetrahydrodiazepine-5,7-dione core. Compounds from this series were tested in numerous GPCR assays and demonstrated activity at melanocortin 1 and 4 receptors (MC1R and MC4R). Selected compounds from this series were tested in vivo in Peptide YY (PYY)-induced food intake. Compounds dosed by intracerebroventricular and oral routes reduced PYY-induced food intake and this effect was reversed by the cyclic peptide MC4R antagonist SHU9119.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号